On July 7, Alibaba Health fell 3.28% in regular trading, trading at HK$3.25 per share, with turnover of HK$193 million.

On the news front, UBS maintained its Sell rating on Alibaba Health and further cut its target price from HK$3.6 to HK$3.1, while lowering earnings forecasts for fiscal years 2027 to 2029 by 5%. UBS projects revenue and adjusted net profit compound annual growth rates of 12% and 5% respectively for fiscal years 2026 to 2029, citing slowing revenue growth and margin pressure from increased investment in AI and supply chain.

Meanwhile, the healthcare e-commerce sector came under broad selling pressure, with peer JD Health declining 4.71% and PA Good Doctor falling 5.0%, creating additional drag on Alibaba Health. The company had reported solid fiscal year 2026 results on July 6, with revenue of RMB 34.255 billion (up 12%) and net profit of RMB 1.936 billion (up 35.2%), but these were offset by the negative brokerage sentiment and sector weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)